Loading...
XNAS
DVAX
Market cap1.29bUSD
Dec 04, Last price  
10.96USD
1D
-0.09%
1Q
8.95%
Jan 2017
177.47%
IPO
-87.82%
Name

Dynavax Technologies Corp

Chart & Performance

D1W1MN
XNAS:DVAX chart
P/E
47.13
P/S
4.64
EPS
0.23
Div Yield, %
—
Shrs. gr., 5y
13.11%
Rev. gr., 5y
51.08%
Revenues
277m
+19.36%
14,655,0004,847,00014,093,00037,094,00040,318,00023,950,00021,614,0009,714,00011,251,00011,032,0004,050,00011,043,000327,0008,198,00035,219,00046,551,000439,442,000722,683,000232,284,000277,246,000
Net income
27m
P
-20,555,000-52,052,000-59,971,000-20,829,000-30,565,000-57,308,000-48,597,000-69,949,000-66,720,000-90,722,000-106,794,000-112,444,000-95,154,000-158,899,000-151,397,000-91,776,00076,713,000293,156,000-6,389,00027,309,000
CFO
67m
-33.86%
-22,858,000-37,240,000-32,032,000-17,035,000-33,552,000-51,370,000-47,116,000-43,809,000-58,673,000-73,738,000-92,559,000-107,051,000-77,518,000-131,301,000-121,252,000-92,251,000335,528,00062,716,000100,563,00066,512,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
URL
https://www.dynavax.com/
IPO date
Feb 19, 2004
Employees
351
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT